Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Drug Profile

Autologous non-bulbar dermal sheath fibroblast therapy - RepliCel Life Sciences

Alternative Names: NBDS fibroblast therapy - RepliCel; RCS-01; RCT-01; RCT-A-01; RCT-P-01; RepliCel Tendon-01; Skin aging therapy - RepliCel; Skin rejuvenation - RepliCel; Tendon repair - RepliCel

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator RepliCel Life Sciences; Royal National Orthopaedic Hospital; Royal University Hospital
  • Class Fibroblast cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Tendon injuries
  • Phase I Skin aging

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tendon injuries in United Kingdom (Intralesional, Injection)
  • 20 Apr 2016 RepliCel completes enrolment in its phase I trial for Skin aging in Germany (9194619; NCT02391935)
  • 20 Apr 2016 RepliCel completes enrolment in its phase I/II trial for Tendon injuries in Canada (9194619; NCT02330146)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top